The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
about
Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis BComparison of hepatocellular carcinoma in Eastern versus Western populations.Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in Hepatocellular CarcinomaRecent Advances in CT and MR Imaging for Evaluation of Hepatocellular CarcinomaRecent advances in radiofrequency ablation for the management of hepatocellular carcinoma.Hepatocellular carcinoma surveillance at 4- vs. 12-month intervals for patients with chronic viral hepatitis: a randomized study in community.Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinomaHepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.Is 3-Tesla Gd-EOB-DTPA-enhanced MRI with diffusion-weighted imaging superior to 64-slice contrast-enhanced CT for the diagnosis of hepatocellular carcinoma?Transcatheter arterial chemoembolization: history for more than 30 years.Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance ImagingGadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians.Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative studyHepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment.When to Perform Surgical Resection or Radiofrequency Ablation for Early Hepatocellular Carcinoma?: A Nomogram-guided Treatment Strategy.Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging.Radiofrequency ablation of high-grade dysplastic nodules.Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.Future treatment option for hepatocellular carcinoma: a focus on brivanib.Hepatocellular carcinoma and vitamin D: a review.Diagnostic imaging of hepatocellular carcinoma: recent progress.The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011.Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis.Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease.Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.Breakthrough Imaging in Hepatocellular CarcinomaHepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.Evaluation of a bioresorbable drug delivery system for the treatment of hepatocellular carcinoma.Early hepatocellular carcinoma: definition and diagnosis.Transarterial chemoembolization vs. radiofrequency ablation for the treatment of single hepatocellular carcinoma 2 cm or smaller.Signaling pathway/molecular targets and new targeted agents under development in hepatocellular carcinomaLiver Cancer Working Group report.Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy.[Radiological diagnosis of primary hepatic malignancy].Hypointense hepatocellular nodules on hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI: can increasing the flip angle improve conspicuity of lesions?Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study.Improvement and multicenter evaluation of the analytical performance of an automated chemiluminescent immunoassay for alpha fetoprotein.Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.
P2860
Q24200785-A488A8BE-7B36-4292-83F8-F64C4CACCEBEQ30245396-A51311C8-D05A-41D2-BE9B-9221BB1783BAQ30388235-B453D9C9-5A57-4EBD-82E8-083C3D2991D6Q30448049-B9951C49-1FD9-464A-A1B3-186E48A9D3A3Q30460837-1F5A96E6-1226-4E0F-A70F-13E0A7C82493Q33405296-AFE58801-441A-4AF2-89D3-F328A87ED538Q34292971-241B1DAC-3440-4FBA-A0F0-50C05401536EQ34321931-002568A4-6A59-435F-A2EB-6C52AB8D509BQ34466458-4C8D5E2F-C05E-4BC7-8F4A-165DCC305A7BQ34642418-BCEB4DA1-B83C-48CF-809C-3CEE12958336Q35148664-7B84AD9A-6B10-486F-A262-C48CBD83B124Q35207733-9CED2F4C-6FAB-4554-91FF-6278BCC01AB9Q36230740-BB50D441-0BB1-4CFE-91FB-F8E65E756AA9Q36423166-AE142D26-935E-42AE-9F46-9476B56DB1C4Q37176195-177F7917-FE1E-400C-9C76-CB156BC4E53EQ37317479-98D51835-833A-41BA-89DE-D0702FA4F522Q37910079-BB506726-CB34-417D-8CF5-428BC90E23A5Q37914630-9D5FB1BF-F8B0-46FC-83F2-9A7DD0A66CECQ37914636-781A937D-A845-4F2F-84FB-6ABD3F9BFF5BQ37924314-106EB1E6-DB8D-4984-9CD1-A964D8708BF3Q37972809-C2C664B7-808A-45D8-BE80-BFA687D52E7AQ37995237-696368D8-163B-4A65-B750-73E814DC2C79Q38032906-22DBD7F5-947B-4219-B430-2CAE9752EB5BQ38146836-672A20B1-65D9-4D7A-A674-7A21E79C1BC9Q38543942-AE16E651-9C17-441B-B4D1-BDD9A5FEB4B0Q38676421-A3BD4B40-8167-435A-B2E3-1887FFE36695Q38969727-E520D605-F6D5-47A7-BD8B-76269E945584Q39051743-7C4B21EB-F3DB-433F-9C58-FF421B92BFF2Q39439093-ABE4FCF0-98CB-4ADF-A992-5C82FCFE6672Q41824372-422B2EB7-CF53-4742-B83A-E6FFAD976DD3Q42212138-DF43D40F-8386-4E14-A329-8B20FC74F97BQ42341423-745B7614-921F-4002-AE84-6332EDA88676Q42876514-5977FA9E-6E73-4054-9724-A22B783DC2B8Q43047099-9874E8C3-30C2-481C-8B8F-FFA3EB0A5B21Q43954477-22290724-A7D5-4F13-801D-DCEC150FC39CQ46843205-E10A4620-663C-4353-9A0E-B202ACA8C64EQ49608357-F44D4198-3E06-4636-82F3-C45190EAACDCQ50998731-FAC3007E-F318-4A7A-87D9-A38B388CA625Q51541140-09CF4182-53AC-4AE6-94A8-CF8EB9CD790CQ53065079-42F3FF2E-8E18-42DD-989A-326A5D42DF4C
P2860
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@en
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@nl
type
label
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@en
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@nl
prefLabel
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@en
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@nl
P2860
P1476
The 2008 Okuda lecture: Manage ...... to molecular targeted therapy.
@en
P2860
P304
P356
10.1111/J.1440-1746.2009.06207.X
P577
2010-03-01T00:00:00Z